Tarsus to Participate in Upcoming Investor Conferences
Tarsus Pharmaceuticals (NASDAQ: TARS) has announced its management team's upcoming participation in two major investor conferences in February 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tarsus Pharmaceuticals (NASDAQ: TARS) has announced its management team's upcoming participation in two major investor conferences in February 2025. The company will engage in fireside chats at:
• The Guggenheim SMID Cap Biotech Conference on Thursday, February 6th, at 6:00 a.m. PT / 9:00 a.m. ET
• The Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12th, at 7:00 a.m. PT / 10:00 a.m. ET
Interested parties can access a live webcast through the events section of the Tarsus website. Replay recordings will be made available within 48 hours of each event and will remain accessible for a time.
Details
News Market Reaction – TARS
The recorded move for TARS in the trading session of this news was +3.90%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in fireside chats at two upcoming investor conferences:
- The Guggenheim SMID Cap Biotech Conference on Thursday, February 6th, at 6:00 a.m. PT / 9:00 a.m. ET
- The Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12th, at 7:00 a.m. PT / 10:00 a.m. ET
A live webcast and additional information can be accessed on the events section of the Tarsus website. The replay will be available on the Tarsus website within 48 hours and will be archived for a limited time.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution,
Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com
Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.